Keele Research Repository
Explore the Repository
Law, ZK, Appleton, JP, Scutt, P, Roberts, I, Al-Shahi Salman, R, England, TJ, Werring, DJ, Robinson, T, Krishnan, K, Dineen, RA, Laska, AC, Lyrer, PA, Egea-Guerrero, JJ, Karlinski, M, Christensen, H, Roffe, C, Bereczki, D, Ozturk, S, Thanabalan, J, Collins, R, Beridze, M, Ciccone, A, Duley, L, Shone, A, Bath, PM, Sprigg, N and Investigators, TICH-2 (2021) Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial. Stroke, 53 (4). pp. 1141-1148. ISSN 1524-4628
STROKEAHA.121.035191.pdf - Published Version
Download (319kB) | Preview
Abstract
BACKGROUND: Seeking consent rapidly in acute stroke trials is crucial as interventions are time sensitive. We explored the association between consent pathways and time to enrollment in the TICH-2 (Tranexamic Acid in Intracerebral Haemorrhage-2) randomized controlled trial.
METHODS: Consent was provided by patients or by a relative or an independent doctor in incapacitated patients, using a 1-stage (full written consent) or 2-stage (initial brief consent followed by full written consent post-randomization) approach. The computed tomography-to-randomization time according to consent pathways was compared using the Kruskal-Wallis test. Multivariable logistic regression was performed to identify variables associated with onset-to-randomization time of <= 3 hours.
Results: Of 2325 patients, 817 (35%) gave self-consent using 1-stage (557; 68%) or 2-stage consent (260; 32%). For 1507 (65%), consent was provided by a relative (1 stage, 996 [66%]; 2 stage, 323 [21%]) or a doctor (all 2-stage, 188 [12%]). One patient did not record prerandomization consent, with written consent obtained subsequently. The median (interquartile range) computed tomography-to-randomization time was 55 (38-93) minutes for doctor consent, 55 (37-95) minutes for 2-stage patient, 69 (43-110) minutes for 2-stage relative, 75 (48-124) minutes for 1-stage patient, and 90 (56-155) minutes for 1-stage relative consents (P<0.001). Two-stage consent was associated with onset-to-randomization time of <= 3 hours compared with 1-stage consent (adjusted odds ratio, 1.9 [95% CI, 1.5-2.4]). Doctor consent increased the odds (adjusted odds ratio, 2.3 [1.5-3.5]) while relative consent reduced the odds of randomization <= 3 hours (adjusted odds ratio, 0.10 [0.03-0.34]) compared with patient consent. Only 2 of 771 patients (0.3%) in the 2-stage pathways withdrew consent when full consent was sought later. Two-stage consent process did not result in higher withdrawal rates or loss to follow-up.
Conclusions: The use of initial brief consent was associated with shorter times to enrollment, while maintaining good participant retention. Seeking written consent from relatives was associated with significant delays.
Item Type: | Article |
---|---|
Additional Information: | © 2021 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. |
Uncontrolled Keywords: | cerebral hemorrhage; humans; informed consent; logistic models; lost to follow-up; tranexamic acid |
Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
Divisions: | Faculty of Medicine and Health Sciences > School of Pharmacy and Bioengineering |
Related URLs: | |
Depositing User: | Symplectic |
Date Deposited: | 15 Dec 2021 12:51 |
Last Modified: | 20 May 2022 09:45 |
URI: | https://eprints.keele.ac.uk/id/eprint/10389 |